Full Text
Estimation of the Budget Saving Potential Due to the Introduction of an Etanercept Biosimilar (SB4) for the Treatment of Approved Adult Etanercept Indications in Belgium

Abstract

Authors

E Psachoulia A Bresson

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×